AbbVie Inc.

New York Stock Exchange
Back to all articles
Bullish +65

ChatGPT Stock Advice: AbbVie Inc. (ABBV) Among Top Stock Recommendations

📈 AbbVie is included in a list of top 12 stock recommendations generated by ChatGPT based on historical trends and macroeconomic resilience.

💰 Q1 fiscal 2025 net revenues reached $13.3 billion, marking a 9.8% operational increase from the prior year.

📊 The company reported adjusted diluted EPS of $2.46, beating guidance by 10 cents and raising full-year guidance to $12.09-$12.29.

🏥 AbbVie secured FDA approval for RINVOQ (upadacitinib) for treating giant cell arthritis in adults following European Commission authorization.

📈 Morgan Stanley raised its price target from $241 to $250 per share while maintaining an Overweight rating on the stock.

🤝 Wall Street analysts maintain a consensus Buy rating with an average projected share price upside of nearly 7%.

🏦 Insider Monkey data indicates that 85 prominent hedge funds held stakes in AbbVie as of Q4 2024.

📉 ChatGPT ranked AbbVie 11th among its top 12 picks, favoring AI stocks for higher potential returns despite ABBV's solid performance.

Bullish Signals
  • AbbVie reported Q1 fiscal 2025 net revenues of $13.3 billion, a 9.8% operational growth that exceeded market expectations.
  • The company delivered adjusted diluted EPS of $2.46, which was 10 cents above its own guidance midpoint.
  • Morgan Stanley increased its price target from $241 to $250 per share following the earnings beat.
  • AbbVie successfully raised its full-year adjusted diluted EPS guidance range to $12.09-$12.29.
  • The company received FDA approval for RINVOQ (upadacitinib) for treating giant cell arthritis in adults, expanding its therapeutic portfolio.
  • Wall Street analysts hold a consensus Buy rating with an average projected upside of nearly 7%.
Full Analysis
AbbVie Inc. (NYSE: ABBV) is highlighted as one of the top 12 stock recommendations generated by ChatGPT, based on criteria including historical performance and economic resilience. The article contextualizes this recommendation within a volatile 2025 market environment driven by trade wars, noting that while broad indices have declined year-to-date, AI adoption could drive future rallies. The core financial news for AbbVie comes from its first-quarter fiscal 2025 results, which exceeded expectations with total net revenues of $13.3 billion, representing a 9.8% operational growth. The company delivered adjusted diluted earnings per share (EPS) of $2.46, surpassing analyst guidance by 10 cents and raising its full-year EPS guidance to a range of $12.09 to $12.29. Following the strong earnings report, Wall Street sentiment remains positive, with Morgan Stanley raising its price target from $241 to $250 per share while maintaining an Overweight rating. Additionally, AbbVie received regulatory approval for RINVOQ (upadacitinib) for treating giant cell arthritis in adults, a development supported by recent European Commission authorization. Analyst consensus currently rates ABBV as a Buy with an average projected upside of nearly 7%, and data from Q4 2024 shows that 85 prominent hedge funds hold stakes in the company. Despite these positive fundamentals, the article notes that ChatGPT ranked AbbVie 11th among its top picks, suggesting the AI model favors high-growth AI stocks over established pharmaceuticals for maximum returns.